Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03381183 · ClinicalTrials.gov registry record · Phase 1
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03381183 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 19 participants.
The verdict
NCT03381183, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the IRX-2 regimen and Durvalumab, will have a tolerable safety profile and will increase the intratumoral immune profile compared with the pretreatment tumors.
Interventions
- DRUG Durvalumab
- DRUG IRX-2 Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-08-21 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03381183
The ClinicalTrials.gov registry entry for NCT03381183 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT03381183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03381183 about?
NCT03381183 is a clinical study titled "IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma". The purpose of this study is to see if the IRX-2 regimen and Durvalumab, will have a tolerable safety profile and will increase the intratumoral immune profile compared with the pretreatment tumors.
What is the current status of trial NCT03381183?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-08-21. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT03381183?
The interventions under investigation include: Durvalumab (DRUG), IRX-2 Regimen (DRUG).
Who is sponsoring clinical trial NCT03381183?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.